Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
2.
Am Heart J ; 136(4 Pt 1): 741-8, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9778080

ABSTRACT

BACKGROUND: This study was designed to investigate the efficacy of alteplase double-bolus dosing compared with the front-loaded 90-minute infusion regimen in patients with acute myocardial infarction. Recent pilot studies have suggested that bolus dosing may provide improved efficacy in establishing early, complete, and sustained patency of the infarct-related artery in the thrombolytic treatment of acute myocardial infarction. METHODS AND RESULTS: In this multicenter, randomized, open-label trial, 461 patients with acute myocardial infarction received 100 mg alteplase as a front-loaded 90-minute infusion (15 mg bolus, then 50 mg over a 30-minute period, then 35 mg over a 60-minute period) or double bolus (two 50 mg bolus injections 30 minutes apart). All patients also received intravenous heparin and oral aspirin during and after alteplase treatment. The 90-minute angiographic patency rates were 74.5% in the double-bolus group and 81.4% in the infusion group (p = 0.08). Patency rates were also comparable for the two groups at 60 minutes (76.8% vs 77.5%) and 24 hours (95.5% vs 93.5%) after initiation of treatment. In-hospital mortality rates were 4.5% in the bolus group and 1.3% in the infusion group (p = 0.04); 30-day mortality rates were 4.5% and 1.7%, respectively (p = NS). The two-groups were comparable in frequency of all other adverse events. CONCLUSIONS: Double-bolus alteplase administration produced reperfusion rates comparable to front-loaded infusion, but in-hospital and 30-day mortality rates were higher in the double-bolus group. These findings are in agreement with those of the COBALT megatrial, which also reported a trend to higher mortality rates with double-bolus dosing.


Subject(s)
Myocardial Infarction/diagnostic imaging , Myocardial Infarction/drug therapy , Plasminogen Activators/administration & dosage , Tissue Plasminogen Activator/administration & dosage , Aged , Canada , Coronary Angiography , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Injections, Intravenous , Male , Middle Aged , Treatment Outcome , United Kingdom , United States
3.
QJM ; 91(11): 719-25, 1998 Nov.
Article in English | MEDLINE | ID: mdl-10024933

ABSTRACT

Optimal strategies for thrombolysis in myocardial infarction (TIMI) are still being sought because the TIMI 3 flow rates achievable using standard regimens average approximately 60%. Double bolus administration of recombinant tissue plasminogen activator (tPA) is a novel approach with potential for earlier patency combined with ease of administration. We reviewed total patency rates, TIMI 3 patency rates, mortality, stroke and intracranial haemorrhage rates in the major trials of accelerated infusion tPA/bolus tPA/reteplase in acute myocardial infarction. A direct comparison was performed with results of two recent trials of double bolus (two 50 mg boli, 30 min apart) vs. accelerated infusion tPA: the Double Bolus Lytic Efficacy Trial (DBLE), an angiographic study, and the COBALT Trial, a mortality study. The DBLE trial showed equivalent patency rates for accelerated infusion and double bolus administration of tPA. Reviewing other angiographic trials, total patency and TIMI 3 patency rates achievable with double bolus tPA were comparable to those with accelerated infusion tPA or bolus reteplase administration. The COBALT study demonstrated a 30-day mortality of 7.53% in patients treated with accelerated infusion tPA compared with 7.98% for double bolus tPA treated patients. The small excess in mortality with double bolus treatment was confined to the elderly; in those < or = 75 years, mortality rates were 5.6% and 5.7%, for double bolus and accelerated infusion, respectively, and rates for death or non-fatal stroke were 6.35% and 6.3%, respectively. Comparison with other trials demonstrated mortality, stroke and intracranial haemorrhage rates with double bolus treatment similar to those associated with either accelerated infusion tPA or bolus reteplase treatment. Double bolus administration of tPA to patients with acute myocardial infarction is associated with total patency, TIMI 3 patency, mortality, stroke and intracranial haemorrhage rates similar to those associated with either accelerated infusion of tPA or bolus reteplase.


Subject(s)
Fibrinolytic Agents/administration & dosage , Myocardial Infarction/drug therapy , Thrombolytic Therapy/methods , Tissue Plasminogen Activator/administration & dosage , Cerebrovascular Disorders/chemically induced , Fibrinolytic Agents/adverse effects , Humans , Myocardial Infarction/mortality , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Survival Analysis , Thrombolytic Therapy/adverse effects , Thrombolytic Therapy/mortality , Tissue Plasminogen Activator/adverse effects , Treatment Outcome
4.
Clin Cardiol ; 19(10): 829-30, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8896917

ABSTRACT

Pneumococcal pericarditis has been an uncommon condition in recent years. This report describes the case of a 57-year-old woman with sarcoidosis who presented with cardiac tamponade due to pneumococcal pericarditis. She responded to pericardiocentesis and intravenous antibiotic therapy. At 4-month review, she remains well.


Subject(s)
Cardiac Tamponade/diagnosis , Pericarditis/diagnosis , Pneumococcal Infections/diagnosis , Sarcoidosis/complications , Anti-Bacterial Agents/therapeutic use , Cardiac Tamponade/complications , Cardiac Tamponade/therapy , Female , Follow-Up Studies , Humans , Middle Aged , Pericardial Window Techniques , Pericarditis/complications , Pericarditis/therapy , Pneumococcal Infections/complications , Pneumococcal Infections/therapy
5.
Postgrad Med J ; 71(840): 627-9, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8545294

ABSTRACT

We describe a 62-year-old woman in whom systemic lupus erythematosus presented as life-threatening effuso-constrictive pericarditis. Surgical drainage of the pericardium was required and the patient made a satisfactory recovery. At six-months follow-up, while taking hydroxychloroquine and a non-steroidal anti-inflammatory agent, she remains well.


Subject(s)
Lupus Erythematosus, Systemic/complications , Pericarditis, Constrictive/etiology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Female , Humans , Lupus Erythematosus, Systemic/drug therapy , Middle Aged
7.
J Electrocardiol ; 28 Suppl: 184-90, 1995.
Article in English | MEDLINE | ID: mdl-8656109

ABSTRACT

An algorithm for the early detection of acute myocardial infarction (MI) using body surface electrocardiographic potential mapping has been developed. The mapping system consists of a 64-hydrogel electrode harness applied rapidly to the anterior chest, from which electrocardiographic signals are stored on a memory card and processed by computer. At each of the 64 points, QRS and ST-T isointegrals and 10 other features of the QRST segment are measured. Using these measurements, new variables are derived that express the shape of the three-dimensional geometric surface of the map. The isointegrals, features, and shape variables are used in a variety of techniques to discriminate between MI and control subjects. Maps were recorded from 69 patients at initial presentation of chest pain suggestive of acute MI and from 80 healthy control subjects. Using a multiple logistic regression technique, 14 variables were identified that correctly classified 79 of the 80 control subjects (specificity, 98.8%) and 65 of the 69 MI patients (sensitivity, 94.2%). The algorithm based on these 14 variables was applied prospectively to maps recorded on a further 48 control subjects and 59 patients with acute MI. Of the MI patients, 31 had inferior, 13 inferoposterior, 10 anterior, 2 posterior, 1 lateral, 1 inferior with right bundle branch block, and 1 anterior non Q wave MI. The algorithm correctly classified all 48 control subjects (specificity, 100%) and 57 of the 59 MI patients (sensitivity, 96.6%). Marked differences in the three-dimensional geometric map surfaces between the control subjects and MI patients were demonstrated. Variables derived from these surfaces form the basis of an algorithm with a high sensitivity and specificity for the automated detection of acute MI. The design of adaptive algorithms and their application to patients with chest pain and atypical electrocardiographic changes, particularly ST depression, may lead to the earlier detection of MI and greater numbers of patients receiving thrombolytic therapy.


Subject(s)
Body Surface Potential Mapping , Electrocardiography , Myocardial Infarction/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Algorithms , Angina Pectoris/diagnosis , Angina Pectoris/physiopathology , Body Surface Potential Mapping/instrumentation , Body Surface Potential Mapping/methods , Bundle-Branch Block/diagnosis , Bundle-Branch Block/physiopathology , Discriminant Analysis , Electrocardiography/instrumentation , Electrocardiography/methods , Electrodes , Equipment Design , Female , Humans , Hydrogel, Polyethylene Glycol Dimethacrylate , Image Processing, Computer-Assisted , Logistic Models , Male , Middle Aged , Myocardial Infarction/drug therapy , Myocardial Infarction/physiopathology , Polyethylene Glycols , Prospective Studies , Reproducibility of Results , Sensitivity and Specificity , Signal Processing, Computer-Assisted , Thrombolytic Therapy
8.
J Electrocardiol ; 27 Suppl: 117-20, 1994.
Article in English | MEDLINE | ID: mdl-7884345

ABSTRACT

Using a newly developed 64-electrode portable mapping device, QRS and ST-T isointegral maps were compared in 194 control subjects and 101 patients. One hundred ninety-four control subjects (mean age, 48 years; 120 men) with no history of cardiac disease were selected randomly and mapped. One hundred one patients (mean age, 62 years; 77 men) were mapped at presentation of chest pain suggestive of first myocardial infarction (MI); all patients had classic 12-lead electrocardiographic findings--46 with anterior and 55 with inferior MI. The diagnosis was confirmed in all cases by a significant rise in serial cardiac enzymes. The mean delay between onset of chest pain to map recording was 163 minutes. Of the 101 patients, 78 were first mapped outside the hospital. Applying discriminant function analysis to the isointegral measurements made on the control subjects and on the first map of MI patients achieved a correct classification of 97% of the control subjects (189 of 194) and 72% of the anterior (33 of 46) and 76% of the inferior (42 of 55) MI groups. This preliminary study suggests that discriminant function analysis, based on isointegral maps, not only provides a method of separating control subjects from MI patients but that it can also differentiate between types of infarct. Further studies are required to improve the predictive values of discriminant function and to extend the methodology to assess both the site and size of MI.


Subject(s)
Body Surface Potential Mapping , Myocardial Infarction/diagnosis , Adult , Aged , Discriminant Analysis , Electrocardiography , Female , Humans , Male , Middle Aged , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...